RAPP Rapport Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2012593 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-54.0%
TTM EPS YoY-39.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-33.3%
ROA-31.5%
ROIC (approx.)-45.9%
Asset turnover—
Leverage & solvency
Liabilities / assets6.5%
Debt / equity0.00x
Current ratio20.07x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $20.00M | — | $0 | $0 | $0 | — |
| R&D expense | $34.32M | $51.41M | $32.72M | $30.26M | $22.28M | $22.68M | $19.57M | $17.20M |
| SG&A expense | $9.77M | $9.39M | $11.50M | $8.25M | $7.71M | $6.82M | $7.54M | $6.32M |
| Operating income | -$44.09M | -$60.81M | -$24.21M | -$38.51M | -$29.99M | -$29.50M | -$27.11M | -$23.52M |
| Pretax income | — | — | — | — | — | — | — | -$19.98M |
| Net income | -$40.23M | -$56.62M | -$19.86M | -$33.76M | -$26.93M | -$26.73M | -$24.06M | -$19.98M |
| EBITDA | -$43.89M | -$60.59M | -$23.99M | -$38.24M | -$29.73M | -$29.24M | -$26.86M | -$23.26M |
| EPS (basic) | -0.84 | -1.19 | -0.42 | — | -0.71 | -0.75 | -0.68 | — |
| EPS (diluted) | -0.84 | -1.19 | -0.42 | — | -0.71 | -0.75 | -0.68 | — |
| Weighted avg. shares (diluted) | 47.77M | 47.47M | 47.24M | — | 37.93M | 35.44M | 35.27M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $74.75M | $63.61M | $78.06M | $52.65M | $251.36M | $55.07M | $57.60M | $56.80M |
| Short-term investments | $320.27M | $372.46M | $398.73M | $437.89M | $261.67M | $205.38M | $227.78M | $248.47M |
| Receivables | $171,000 | $293,000 | $58,000 | $0 | — | — | — | — |
| Current assets | $407.38M | $446.86M | $484.69M | $498.56M | $520.66M | $270.24M | $290.97M | $309.80M |
| PP&E, net | $1.96M | $2.34M | $2.52M | $2.98M | $3.12M | $3.17M | $3.40M | $3.53M |
| Total assets | $418.56M | $458.98M | $497.60M | $512.43M | $535.32M | $285.50M | $302.05M | $314.93M |
| Current liabilities | $20.30M | $28.42M | $17.90M | $19.05M | $14.32M | $11.88M | $9.38M | $8.77M |
| Total liabilities | $27.37M | $36.06M | $26.09M | $27.78M | $23.71M | $21.98M | $16.22M | $9.51M |
| Shareholders' equity | $391.19M | $422.93M | $471.51M | $484.65M | $511.62M | $263.51M | $285.84M | $305.43M |
| Shares outstanding | 48.09M | 47.96M | 47.81M | 47.77M | 47.65M | 36.50M | 36.50M | 36.58M |
| Cash flow statement | ||||||||
| Operating cash flow | -$41.63M | -$41.45M | -$13.06M | -$24.70M | -$17.46M | -$25.07M | -$20.24M | -$14.45M |
| Capital expenditure | $0 | $78,000 | $86,000 | $169,000 | $134,000 | $22,000 | $291,000 | $226,000 |
| Free cash flow | -$41.63M | -$41.53M | -$13.15M | -$24.87M | -$17.60M | -$25.09M | -$20.53M | -$14.67M |
| Investing cash flow | $51.06M | $25.60M | $37.94M | -$174.32M | -$56.78M | $22.60M | $21.03M | $31.93M |
| Financing cash flow | $1.71M | $1.41M | $531,000 | $311,000 | $270.53M | -$63,000 | $5,000 | $7,000 |
| Depreciation & amortization | $198,000 | $212,000 | $227,000 | $265,000 | $256,000 | $252,000 | $244,000 | $260,000 |
| Stock-based compensation | $7.63M | $7.20M | $6.96M | $5.69M | $4.74M | $4.39M | $4.04M | $3.21M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.